O
OLMA
Olema Pharmaceuticals, Inc.
15.06
-0.06-0.40%After Hours: 15.06 0.00 0.00%16:10 04/02 EDT
OPEN/PREV CLOSE14.69/15.12
TODAY RANGE14.62-15.12
VOL904.35K
MARKET CAP1.31B
52 WEEK RANGE2.860-36.26
AVG VOL (3M)1.68M
% TURNOVER1.04%
TURNOVER--
P/E (TTM)-8.0660
% RANGE3.33%
EPS(TTM)-1.8671
P/E(FORWARD)-6.7534
P/B2.561
BVPS5.88
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.28B
SHARES OUTSTANDING87.16M
NEXT EARNINGS05/11-05/15
FREE FLOAT84.76M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·4d ago
A Look At Olema Pharmaceuticals (OLMA) Valuation After Earnings And New Shelf Registration Filing
Dow Jones·03/27 12:07
Olema Pharmaceuticals Initiated at Peer Perform by Wolfe Research
TipRanks·03/26 20:15
Olema Oncology initiated with a Peer Perform at Wolfe Research
The Motley Fool·03/22 16:28
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
TipRanks·03/21 14:57
LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
Dow Jones·03/19 19:53
Olema Pharmaceuticals Price Target Cut to $40.00/Share From $43.00 by Jefferies
Dow Jones·03/19 19:53
Olema Pharmaceuticals Coverage Assumed by Jefferies at Buy
Benzinga·03/19 19:43
Jefferies Assumes Olema Pharmaceuticals at Buy, Lowers Price Target of $40
Simply Wall St·03/19 16:08
Olema Pharmaceuticals (OLMA) Is Down 6.7% After Posting Wider Losses And Filing New Stock Shelf
TipRanks·03/19 09:20
Olema Oncology assumed with a Buy at Jefferies
Dow Jones·03/18 15:57
Olema Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones·03/18 15:57
Olema Pharmaceuticals Price Target Raised to $58.00/Share From $55.00 by JP Morgan
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.